Elisabeth Rouits

841 total citations
24 papers, 567 citations indexed

About

Elisabeth Rouits is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Elisabeth Rouits has authored 24 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Elisabeth Rouits's work include Cell death mechanisms and regulation (7 papers), Cancer therapeutics and mechanisms (5 papers) and Neutropenia and Cancer Infections (3 papers). Elisabeth Rouits is often cited by papers focused on Cell death mechanisms and regulation (7 papers), Cancer therapeutics and mechanisms (5 papers) and Neutropenia and Cancer Infections (3 papers). Elisabeth Rouits collaborates with scholars based in Switzerland, France and United States. Elisabeth Rouits's co-authors include Érick Gamelin, Alain Morel, Agnès Dumont, M. Boisdron‐Celle, Olivier Guérin, Armel Stockis, Grégoire Vuagniaux, Claudio Zanna, Shikiko Watanabe and Shin Irie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Analytical Chemistry.

In The Last Decade

Elisabeth Rouits

24 papers receiving 556 citations

Peers

Countries citing papers authored by Elisabeth Rouits

Since Specialization

Citations

This map shows the geographic impact of Elisabeth Rouits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Rouits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Rouits more than expected).

Fields of papers citing papers by Elisabeth Rouits

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Rouits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Rouits. The network helps show where Elisabeth Rouits may publish in the future.

Co-authorship network of co-authors of Elisabeth Rouits

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Rouits. A scholar is included among the top collaborators of Elisabeth Rouits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Rouits. Elisabeth Rouits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses 2023 ·Cancer Research ·Quincy S. Chu, Tudor–Eliade Ciuleanu, Rodryg Ramlau, Daniel J. Renouf, Rosalyn A. Juergens, Ewa Kalinka‐Warzocha, Piotr Sawrycki, Jonathan L. Bramson, Brad H. Nelson, (unknown), Daniela A. Sahlender, (unknown), Elisabeth Rouits, (unknown), Franck Brichory, (unknown), M Schenker, Glenwood Goss	1
2	Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck 2023 ·Clinical Pharmacology & Therapeutics ·Yulia Vugmeyster, (unknown), Elisabeth Rouits, Paul M. Diderichsen, Huub Jan Kleijn, (unknown), XiaoZhe Wang, Andreas Schröeder, Kosalaram Goteti, Karthik Venkatakrishnan	3
3	Abstract 5424: Selection of RP3D of xevinapant in combination with CRT in patients with LA SCCHN 2022 ·Cancer Research ·Yulia Vugmeyster, (unknown), Elisabeth Rouits, Paul M. Diderichsen, Huub Jan Kleijn, Kosalaram Goteti, Andreas Schröeder, Karthik Venkatakrishnan	1
4	SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY 2021 ·Hematological Oncology ·Moshe Levy, (unknown), Marek Trněný, Wojciech Jurczak, Halyna Pylypenko, Deepa Jagadeesh, Marc André, Sunita D. Nasta, (unknown), (unknown), Sandrine Micallef, Antoine Attinger, Elisabeth Rouits, (unknown), Heidi Nauwelaerts, Feng Jung Sherida H. Woei-A-Jin	3
5	Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer 2021 ·Clinical and Translational Science ·Carlos Gomez‐Roca, Caroline Even, Christophe Le Tourneau, Neus Basté, Jean‐Pierre Delord, Jérôme Sarini, S. Vergèz, Stéphane Temam, Caroline Hoffmann, Philippe Rochaix, Édith Borcoman, Bruno Gavillet, Elisabeth Rouits, Annick Ménétrey, Franck Brichory, Daniela Purcea, Grégoire Vuagniaux, Claudio Zanna	17
6	Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study 2021 ·Blood ·Moshe Levy, Deepa Jagadeesh, (unknown), Marek Trněný, Wojciech Jurczak, Halyna Pylypenko, Marc André, Sunita D. Nasta, (unknown), Sara Toffanin, Sandrine Micallef, Antoine Attinger, Elisabeth Rouits, (unknown), (unknown), (unknown), Heidi Nauwelaerts, (unknown)	11
7	Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck 2020 ·Clinical Cancer Research ·Christophe Le Tourneau, Yungan Tao, Carlos Gomez‐Roca, Valérie Cristina, Édith Borcoman, Éric Deutsch, Rastislav Bahleda, Valentin Calugaru, A. Modesto, Elisabeth Rouits, Kathrin Gollmer, Grégoire Vuagniaux, (unknown), Claudio Zanna, Sergio Szyldergemajn, Jean‐Pierre Delord, Jean Bourhis	22
8	PV-0518: Phase 1 study of Debio 1143 in combination with Concurrent Chemo-Radiotherapy in LA-SCCHN 2016 ·Radiotherapy and Oncology ·Tao Yu, C. Le Tourneau, Hasna Bouchaab, J.P. Delord, Valentin Calugaru, (unknown), Bruno Gavillet, Elisabeth Rouits, Claudio Zanna, (unknown), Éric Deutsch, Jean Bourhis	4
9	Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study 2015 ·Clinical Lymphoma Myeloma & Leukemia ·John F. DiPersio, Harry P. Erba, Richard A. Larson, Selina M. Luger, Martin S. Tallman, (unknown), Grégoire Vuagniaux, Elisabeth Rouits, John M. Sorensen, Claudio Zanna	36
10	Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase 2015 ·Annals of Oncology ·Nicolás Isambert, Jean‐Pierre Delord, Jean‐Charles Soria, Antoine Hollebecque, Carlos Gomez‐Roca, Daniela Purcea, Elisabeth Rouits, Riccardo Belli, P. Fumoleau	27
11	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study 2015 ·Cancer Chemotherapy and Pharmacology ·Herbert I. Hurwitz, David C. Smith, Henry C. Pitot, (unknown), Rashmi Chugh, Elisabeth Rouits, Joseph Rubin, John H. Strickler, Grégoire Vuagniaux, John M. Sorensen, Claudio Zanna	61
12	Brivaracetam Single and Multiple Rising Oral Dose Study in Healthy Japanese Participants: Influence of CYP2C19 Genotype 2014 ·Drug Metabolism and Pharmacokinetics ·Armel Stockis, Shikiko Watanabe, Elisabeth Rouits, Kyoko Matsuguma, Shin Irie	49
13	Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). 2014 ·Journal of Clinical Oncology ·John F. DiPersio, Harry P. Erba, Richard A. Larson, Selina M. Luger, Kenneth F. Mangan, Martin S. Tallman, (unknown), Grégoire Vuagniaux, Elisabeth Rouits, Claudio Zanna, John M. Sorensen	2
14	Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment. 2014 ·Journal of Clinical Oncology ·Elisabeth Rouits, Per Olsson, Bruno Gavillet, Annick Ménétrey, (unknown), Claudio Zanna, Grégoire Vuagniaux, Valerie Nicolas‐Métral	1
15	First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results. 2014 ·Journal of Clinical Oncology ·Herbert I. Hurwitz, Henry C. Pitot, David C. Smith, (unknown), Grégoire Vuagniaux, Elisabeth Rouits, Claudio Zanna, John M. Sorensen	2
16	Pharmacokinetics of levetiracetam XR 500 mg tablets 2009 ·Epilepsy Research ·Elisabeth Rouits, (unknown), (unknown), (unknown), Armel Stockis, Maria Laura Sargentini‐Maier	25
17	Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients 2008 ·British Journal of Cancer ·Elisabeth Rouits, Virginie Charasson, Aurélie Pétain, Michelle Boisdron-Celle, (unknown), Marianne Fonck, (unknown), (unknown), Alain Morel, Étienne Chatelut, Jacques Robert, Érick Gamelin	49
18	Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity 2004 ·Clinical Cancer Research ·Elisabeth Rouits, M. Boisdron‐Celle, Agnès Dumont, Olivier Guérin, Alain Morel, Érick Gamelin	211
19	Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice 2003 ·Journal of Chromatography B ·Elisabeth Rouits, Michelle Boisdron-Celle, Alain Morel, Érick Gamelin	17
20	Non-linear pharmacokinetics of irinotecan in mice 2002 ·Anti-Cancer Drugs ·Elisabeth Rouits, Sylvie M. Guichard, Pierre Canal, Étienne Chatelut	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact